Login to Your Account



Merck drops vintafolide, returns rights to Endocyte

By Michael Fitzhugh
Staff Writer

Thursday, June 19, 2014

Endocyte Inc. shares plummeted Tuesday as Merck & Co. Inc. pulled the plug on its $1 billion vintafolide partnership, returning global rights to Endocyte's most advanced small-molecule drug conjugate (SMDC).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription